Genentech: Noel Dybdal | Senior Director and Senior Principal Scientist, Safety Assessment Pathology, Department of Development Sciences

Scientists / Our Scientists

"The environment at Genentech is always stimulating and the opportunity to work with some of the brightest and most innovative scientists imaginable working toward a common and urgent goal of providing new and better options for patients is continuously rewarding. The urgency of our mission drives us to bring our best selves to work every day."

Years at Genentech

Publications

Awards & Honors

Following completion of residency training in Pathology and post-doctoral work in Endocrine Pathology, I joined Genentech as a Scientist-Pathologist in 1992. I was most attracted by the Genentech reputation for rigor. Happily, given my interest and training in pathology, receptor ligand biology and radioimmunoassay and immunohistochemistry techniques, I became involved early with the oncology program teams, in particular the anti-HER2 projects. My responsibilities have also included growing the Safety Assessment Pathology group to meet the needs of all Genentech programs.

Featured Publication

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.

Breast Cancer Res Treat. 2005 Sep; 93(1): 3-11.

Dybdal N, Leiberman G, Anderson S, McCune B, Bajamonde A, Cohen RL, Mass RD, Sanders C, Press MF.

View Abstract on PubMed.

Providing expertise in pathology, veterinary medicine and comparative medicine to enhance the timely development of safe Genentech medicines. Working in a highly collaborative environment with colleagues from across the gRED and Product Development to design and implement programs in support of optimal drug candidate development at Genentech. Building and supporting an industry leading Safety Assessment Pathology group. Actively driving innovation in preclinical drug development approaches, supporting and participating in internal and cross-industry efforts to increase drug development efficiency and success while building data to support regulatory acceptance.

Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody

JCI insight, ISSN: 23793708

Karin Staflin; Christina L. Zuch de Zafra; Leah Schutt; Vanessa Clark; Fiona Zhong; Maria Hristopoulos; Robyn Clark; Ji Li; Mary Mathieu; Xiaocheng Chen; Jennifer A. Johnston; Justin Low; Ryan Ybarra; Dionysos S. Slaga; Yang; Meric A. Ovacik; Noel Dybdal; Klara Totpal; Melissa Junttila; Diego Ellerman; Genee Y. Lee; Dennis; Prell; Teemu T. Junttila

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Noel Dybdal

Senior Director and Senior Principal Scientist, Safety Assessment Pathology, Department of Development Sciences

Featured Publication

Determination of HER2 gene amplification by fluorescence in situ hybridization and concordance with the clinical trials immunohistochemical assay in women with metastatic breast cancer evaluated for treatment with trastuzumab.